| Code | CSB-RA011580MB2HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is developed as a research-grade biosimilar to MK-1966, targeting interleukin-10 (IL-10), a potent immunoregulatory cytokine that plays a central role in controlling inflammatory responses. IL-10 is primarily produced by various immune cells including regulatory T cells, macrophages, and dendritic cells, where it functions to suppress pro-inflammatory cytokine production and limit excessive immune activation. This cytokine exhibits complex and context-dependent effects in disease settings, promoting anti-inflammatory responses in autoimmune conditions while potentially suppressing anti-tumor immunity in the cancer microenvironment, making it a critical target for understanding immune homeostasis and dysfunction.
MK-1966 represents a therapeutic antibody originally developed for cancer immunotherapy applications, designed to block IL-10 signaling and restore effective anti-tumor immune responses. This biosimilar antibody provides researchers with a valuable tool for investigating IL-10-mediated immune regulation, exploring therapeutic interventions in oncology and inflammatory diseases, and studying the molecular mechanisms underlying cytokine signaling networks. It supports diverse experimental approaches in immunology, cancer biology, and therapeutic antibody development.
There are currently no reviews for this product.